In multiple pre-clinical studies, they have been shown to activate antigen-specific CD8+ T cell responses [15,19,26,27] and generate protective immunity in tumor models, e.g., B16-OVA melanoma [7,13,19,23,26,27], and against multiple infectious diseases, e.g., H1N1 influenza [11], Listeria monocytogenes [7,12], Trypanosoma cruzi [13] and Mycobacterium tuberculosis [14]. Here, CD8A is linked to melanoma.